Wall Street analysts’ estimates
Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018. Also, the company is expected to report a net adjusted income of ~$20.0 million during Q1 2019.
The above chart shows analyst recommendations for Haemonetics stock over the last 12 months.
Haemonetics’s stock has increased by nearly 137.2% over the last 12 months and ~66.5% in 2018 year-to-date. Analysts estimate that the stock might fall ~10.2% over the next 12 months. Wall Street analysts have a 12-month target price of $86.86 per share as compared to the last price of $96.71 per share as of August 3.
As of August 3, nine analysts were tracking Haemonetics. Of these nine analysts, two analysts recommend a “strong buy,” two analysts recommend a “buy,” and five analysts recommend a “hold.” There aren’t any “sell” ratings on Haemonetics. The consensus rating for Haemonetics stands at 2.93, which represents a “hold” for value investors.
As of August 3, Haemonetics trades at a forward price-to-earnings multiple of 38.3x as compared to the industry average of 19.9x. Also, the forward EV-to-EBITDA multiple for Haemonetics is 18.9x as compared to the industry average of ~15.3x.